Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | POLR1A | O95602 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249809 | 0.93 | SRC (0.41) | ADORA2AADORA1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2246694 | 0.90 | HSD17B10 (0.38) | KDM4EALDH1A1HSD17B10KMT2APOLB | |
| SCHEMBL2248666 | 0.87 | SRC (0.40) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL2248615 | 0.82 | FGFR1 (0.39) | SRCWEE1 | |
| SCHEMBL2248978 | 0.79 | POLR1A (0.38) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL2247838 | 0.78 | SRC (0.55) | SRCWEE1FLT3SYK | |
| SCHEMBL2252397 | 0.76 | FGFR1 (0.37) | SRCWEE1 | |
| SCHEMBL2247929 | 0.76 | SRC (0.37) | SRCWEE1 | |
| SCHEMBL2249782 | 0.75 | FGFR1 (0.32) | SRCTSHR | |
| SCHEMBL2247060 | 0.73 | HTR4 (0.38) | KDM4EALDH1A1HSD17B10KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-8518958-B2 | Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Valo Health, LLC | 2011-08-18 | — | — | US | claimed |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8518958-B2 | Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Valo Health, LLC | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | ADORA2A 996/4885ADORA1 1269/4885KDM4E 966/4885 |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | ADORA2A 996/4885ADORA1 1269/4885KDM4E 966/4885 |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | ADORA2A 996/4885ADORA1 1269/4885KDM4E 966/4885 |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | ADORA2A 996/4885ADORA1 1269/4885KDM4E 966/4885 |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | ADORA2A 996/4885ADORA1 1269/4885KDM4E 966/4885 |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | ADORA2A 996/4885ADORA1 1269/4885KDM4E 966/4885 |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | ADORA2A 996/4885ADORA1 1269/4885KDM4E 966/4885 |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | DCK, PDXK, TK1 | ADORA2A 941/4885ADORA1 1184/4885KDM4E 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.